Announced Fri, 10 Jul · 22:53 IST
HCC appoints Nakul Pasricha as Independent Director for 5 years
Management Changes View source PDF
HCC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.6%1-day move
₹23.96
prior close
₹23.59
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4+1.2+1.9+2.0-3.6-2.8-4.2-6.5-4.5-7.8————
Up moveDown movePending
AI summary
HCC has appointed Mr. Nakul Pasricha (DIN: 03176843) as an Additional Non-Executive Independent Director for 5 years from July 10, 2026, subject to shareholder approval within 3 months. Pasricha has over 27 years of experience and is currently MD and CEO of PharmaSecure. He is not related to any existing director and is not debarred by SEBI. The appointment was made via circular resolution on the recommendation of the Nomination and Remuneration Committee.
Likely market impact
Standard independent director addition to strengthen the board. No material impact on operations or share price expected.